Aberrant DNA repair as a potential contributor for the clonal evolution in subsets of anaplastic thyroid carcinomas arising through dedifferentiation: implications for future therapeutic algorithms?

Abstract

Well-differentiated thyroid carcinoma (WDTC, including papillary thyroid carcinoma and follicular thyroid carcinoma) are fairly slow-growing tumors with an overall low mortality due to the efficacy of combinatory surgery and postoperative radioiodine therapy. Subsets of WDTCs may dedifferentiate into poorly differentiated thyroid carcinoma (PDTC) and anaplastic thyroid carcinoma (ATC), of which especially the latter has an exceptionally poor patient outcome. The underlying genetics responsible for this tumor progression is only partly understood, and is complicated by the fact that subgroups of ATCs are thought to arise de novo without a demonstrable, pre-existing WDTC. Even so, recent advances using next generation sequencing (NGS) techniques have identified a genetic link between WDTCs and ATCs, suggesting a step-wise accumulation of mutations driving the loss of differentiation for most cases. In this Commentary, recent findings from an NGS study on synchronous FTC, PDTC, and ATC tumor components from the same patient are highlighted. By using whole-genome data, clonality analyses identified a chief ancestral clone carrying mutations in TP53-associated signaling networks regulating genes involved in DNA repair, with sub-clones in each tumor component that were identified also in the less differentiated, neighboring tumor. Moreover, mutational signatures suggested a general mismatch repair (MMR) deficiency along with microsatellite instability. These findings support the chained progression model of dedifferentiation in thyroid cancer, and pinpoint a central role for defective DNA repair. Since effective treatment modalities for ATCs are urgently needed, studies regarding therapeutic agents specifically targeting defective MMR in dedifferentiated thyroid carcinoma could be pursued.

Keywords

DNA repair / mismatch repair / P53 / thyroid carcinoma / dedifferentiation / anaplastic thyroid carcinoma / clone / treatment

References

[1] Maniakas A,Busaidy NL.Evaluation of overall survival in patients with anaplastic thyroid carcinoma, 2000-2019..JAMA Oncol2020;6:1-8 PMCID:PMC7411939

[2] Lennon P,Healy ML.Anaplastic thyroid carcinoma: failure of conventional therapy but hope of targeted therapy..Head Neck.2016;38 Suppl 1:E1122-9

[3] Lloyd RV,Klöppel G.WHO/IARC classification of tumours of endocrine organs.2017;4th editionLyonInternational Agency for Research on Cancer

[4] de Ridder M,Engelsman A.Anaplastic thyroid carcinoma: a nationwide cohort study on incidence, treatment and survival in the Netherlands over 3 decades..Eur J Endocrinol2020;183:203-9

[5] Saini S,Maker AV,Prabhakar BS.Therapeutic advances in anaplastic thyroid cancer: a current perspective..Mol Cancer2018;17:154 PMCID:PMC6198524

[6] Alobuia W,Kebebew E.Contemporary management of anaplastic thyroid cancer..Curr Treat Options Oncol2020;21:78

[7] Molinaro E,Biagini A.Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies..Nat Rev Endocrinol2017;13:644-60

[8] Nylén C,Maréchal-Ross I.Molecular Markers Guiding Thyroid Cancer Management..Cancers (Basel)2020;12: PMCID:PMC7466065

[9] Stenman A,Jatta K.Metastatic anaplastic thyroid carcinoma in complete remission: morphological, molecular, and clinical work-up of a rare case..Endocr Pathol2020;31:77-83

[10] Rosove MH,Glaspy JA.BRAF V600E inhibition in anaplastic thyroid cancer..N Engl J Med2013;368:684-5

[11] Xu B,Dogan S.Dissecting anaplastic thyroid carcinoma: a comprehensive clinical, histologic, immunophenotypic, and molecular study of 360 cases..Thyroid2020; PMCID:PMC7583343

[12] Wallin G,Tallroth-Ekman E.Co-existent anaplastic and well differentiated thyroid carcinomas: a nuclear DNA study..Eur J Surg Oncol1989;15:43-8

[13] Kunstman JW,Goh G.Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing..Hum Mol Genet2015;24:2318-29 PMCID:PMC4380073

[14] Landa I,Boucai L.Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers..J Clin Invest2016;126:1052-66 PMCID:PMC4767360

[15] Shi X,Qu S.Association of TERT promoter mutation 1,295,228 C>T with BRAF V600E mutation, older patient age, and distant metastasis in anaplastic thyroid cancer..J Clin Endocrinol Metab2015;100:E632-7 PMCID:PMC4399285

[16] Oishi N,Ebina A.Molecular alterations of coexisting thyroid papillary carcinoma and anaplastic carcinoma: identification of TERT mutation as an independent risk factor for transformation..Mod Pathol2017;30:1527-37

[17] Capdevila J,Mancuso FM.Early evolutionary divergence between papillary and anaplastic thyroid cancers..Ann Oncol2018;29:1454-60

[18] Dong W,Choi J.Clonal evolution analysis of paired anaplastic and well-differentiated thyroid carcinomas reveals shared common ancestor..Genes Chromosomes Cancer2018;57:645-52

[19] Karger S,Engelhardt C.Distinct pattern of oxidative DNA damage and DNA repair in follicular thyroid tumours..J Mol Endocrinol2012;48:193-202

[20] Santos LS,Bastos HN.Thyroid cancer: the quest for genetic susceptibility involving DNA repair genes..Genes (Basel)2019;10: PMCID:PMC6722859

[21] Siołek M,Gąsior-Perczak D.CHEK2 mutations and the risk of papillary thyroid cancer.Int J Cancer2015;137:548-52

[22] Wójcicka A,Świerniak M.Variants in the ATM-CHEK2-BRCA1 axis determine genetic predisposition and clinical presentation of papillary thyroid carcinoma..Genes Chromosomes Cancer2014;53:516-23 PMCID:PMC4058861

[23] Javid M,Nicolson NG.DNA mismatch repair deficiency promotes genomic instability in a subset of papillary thyroid cancers..World J Surg2018;42:358-66

[24] Genutis LK,Bundschuh RA.Microsatellite instability occurs in a subset of follicular thyroid cancers..Thyroid2019;29:523-9 PMCID:PMC6457885

[25] Wong KS,Alexander EK.Clinicopathologic features of mismatch repair-deficient anaplastic thyroid carcinomas..Thyroid2019;29:666-73

[26] Paulsson JO,Wang N.Whole-genome sequencing of synchronous thyroid carcinomas identifies aberrant DNA repair in thyroid cancer dedifferentiation..J Pathol2020;250:183-94

[27] Deshwar AG,Yung CK.PhyloWGS: reconstructing subclonal composition and evolution from whole-genome sequencing of tumors..Genome Biol2015;16:35 PMCID:PMC4359439

[28] Blackford AN.ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response..Mol Cell2017;66:801-17

[29] Raetz AG.When you’re strange: Unusual features of the MUTYH glycosylase and implications in cancer..DNA Repair (Amst)2019;80:16-25 PMCID:PMC6812671

[30] Chintakuntlawar AV,Smith CY.Expression of PD-1 and PD-L1 in anaplastic thyroid cancer patients treated with multimodal therapy: results from a retrospective study..J Clin Endocrinol Metab2017;102:1943-50

[31] Iyer PC,Gule-Monroe M.Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma..J Immunother Cancer2018;6:68 PMCID:PMC6042271

[32] Capdevila J,Ernst T.PD-1 blockade in anaplastic thyroid carcinoma..J Clin Oncol2020;38:2620-7 PMCID:PMC7476256

[33] Kim ST,Park SH.Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy..Oncotarget2017;8:77415-23 PMCID:PMC5652789

[34] Liu Y,Zhang S.Somatic mutations in genes associated with mismatch repair predict survival in patients with metastatic cancer receiving immune checkpoint inhibitors..Oncol Lett2020;20:27 PMCID:PMC7405634

[35] Hsiehchen D,Samstein RM.DNA repair gene mutations as predictors of immune checkpoint inhibitor response beyond tumor mutation burden..Cell Rep Med2020;1: PMCID:PMC7365618

[36] Samstein RM,Shoushtari AN.Tumor mutational load predicts survival after immunotherapy across multiple cancer types..Nat Genet2019;51:202-6 PMCID:PMC6365097

[37] Ribic CM,Moore MJ.Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer..N Engl J Med2003;349:247-57 PMCID:PMC3584639

[38] Martin SA,Mullarkey M.DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1..Cancer Cell2010;17:235-48 PMCID:PMC2845806

[39] Hewish M,Elliott R.Cytosine-based nucleoside analogs are selectively lethal to DNA mismatch repair-deficient tumour cells by enhancing levels of intracellular oxidative stress..Br J Cancer2013;108:983-92 PMCID:PMC3590674

[40] Martin SA,Barber LJ.Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2..EMBO Mol Med2009;1:323-37 PMCID:PMC3378145

[41] Revannasiddaiah S,Bodh A,Sharma M.Metronomic chemotherapy in anaplastic thyroid carcinoma: a potentially feasible alternative to therapeutic nihilism..Indian J Palliat Care2015;21:245-9 PMCID:PMC4441190

[42] Tallroth E,Lundell G,Einhorn J.Multimodality treatment in anaplastic giant cell thyroid carcinoma..Cancer1987;60:1428-31

[43] Ferrás C,Verspuy JWA.Abrogation of microsatellite-instable tumors using a highly selective suicide gene/prodrug combination..Mol Ther2009;17:1373-80 PMCID:PMC2835239

[44] Begum R.Targeting mismatch repair defects: a novel strategy for personalized cancer treatment..DNA Repair (Amst)2016;38:135-9